Experimental drug may treat social withdrawal symptoms in individuals with fragile X syndrome, the most common known genetic cause of autism.

Submitted by djohnson on September 20, 2012 - 13:44
Source: 
Science Translational Medicine
Link: 
Effects of STX209 (Arbaclofen) on Neurobehavioral Function in Children and Adults with Fragile X Syndrome: A Randomized, Controlled, Phase 2 Trial
Date Published: 
September 19, 2012
Abstract: 

Arbaclofen, also known as STX209, shows promise in its treatment of social symptoms associated with fragile x syndrome.